| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/29/2007 | CA2623176A1 Protein a production and purification without using animal derived components |
| 03/29/2007 | CA2622997A1 A liposome composition to cause lysis of cells and pathogens |
| 03/29/2007 | CA2622704A1 Highly concentrated pourable aqueous solutions of potassium ibuprofen their preparation and their uses |
| 03/28/2007 | EP1767632A2 A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor |
| 03/28/2007 | EP1767575A1 Gel-form water-absorbing material |
| 03/28/2007 | EP1767221A2 Preparation and use of a bivalent vaccine against morphine-heroine addiction |
| 03/28/2007 | EP1767220A1 Eriodictyon extract containing pharmaceuticals for nasal administration |
| 03/28/2007 | EP1767219A2 Stable injectable diclofenac compositions |
| 03/28/2007 | EP1767218A1 Antiinflammatory and analgesic preparation for external use |
| 03/28/2007 | EP1767215A1 Isoflavones against radiation-induced mortality |
| 03/28/2007 | EP1767207A2 Solid Oral Dosage Forms |
| 03/28/2007 | EP1767206A2 Solid Oral Dosage Forms |
| 03/28/2007 | EP1767195A2 Stable spray-dried protein formulations |
| 03/28/2007 | EP1767193A2 Pharmaceutical compositions |
| 03/28/2007 | EP1767192A2 Cationic lipid compositions targeting angiogenic endothelial cells |
| 03/28/2007 | EP1766053A2 Rna-containing microvesicles and methods therefor |
| 03/28/2007 | EP1766017A1 Tumor specific antibody |
| 03/28/2007 | EP1765894A1 Novel temperature and ph sensitive copolymers |
| 03/28/2007 | EP1765426A2 Wound healing polymer compositions and methods for use thereof |
| 03/28/2007 | EP1765413A2 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers |
| 03/28/2007 | EP1765412A2 Multivalent vla-4 antagonists comprising polyethylene glycol moieties |
| 03/28/2007 | EP1765411A2 Polymer-factor ix moiety conjugates |
| 03/28/2007 | EP1765410A2 Method for producing albumen/corticoid conjugates |
| 03/28/2007 | EP1765409A2 Conjugates of antibody and duocarmycin derivatives as antitumor agents |
| 03/28/2007 | EP1765408A2 Polypeptide protracting tags comprising a tetrazole moiety |
| 03/28/2007 | EP1765407A1 Binary thermo-gelling composition |
| 03/28/2007 | EP1765406A1 Delivery agents for enhancing mucosal absorption of therapeutic agents |
| 03/28/2007 | EP1765403A2 Combined active and passive targeting of biologically active agents |
| 03/28/2007 | EP1765394A1 Methods for preparing immunogenic conjugates |
| 03/28/2007 | EP1765385A1 Sustained release vaccine composition |
| 03/28/2007 | EP1765382A1 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides |
| 03/28/2007 | EP1765373A2 Ozonidzed pharmaceutical composition and method |
| 03/28/2007 | EP1765369A2 Process for the preparation of calcium phosphate granules of the hydroxyapatite type |
| 03/28/2007 | EP1765367A1 Phospholipid compositions and methods for their preparation and use |
| 03/28/2007 | EP1765356A1 Spray composition comprising a combination of calcitriol and clobetasol propionate, an alcoholic phase, at least one volatile silicone and one non volatile oily phase |
| 03/28/2007 | EP1765340A1 Sustained release composition for oral administration of niacin |
| 03/28/2007 | EP1765310A2 A mixture for transdermal delivery of low and high molecular weight compounds |
| 03/28/2007 | EP1765299A1 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight |
| 03/28/2007 | EP1765290A2 Stabilised supersaturated solid solutions of steroidal drugs |
| 03/28/2007 | EP1765283A2 Pharmaceutical compositions |
| 03/28/2007 | EP1765162A1 Contrast agents for magnetic resonance imaging |
| 03/28/2007 | EP1765081A1 Hydrogen peroxide-based skin disinfectant |
| 03/28/2007 | EP1684700B1 Use of perfluoropolyether phosphates as stabilizing agents for polyphenols in cosmetic and/or dermatological compositions |
| 03/28/2007 | EP1513555B1 Formulations of quinapril and related ace inhibitors |
| 03/28/2007 | EP1448710B1 Ph responsive biodegradable polylactic acid derivatives forming polymeric micelles and uses thereof for poorly water soluble drug delivery |
| 03/28/2007 | EP1416958B1 Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other |
| 03/28/2007 | EP1363676B1 Method of enhancing delivery of a therapeutic nucleic acid |
| 03/28/2007 | EP1292381A4 Process and device for producing liquid dosage formulations |
| 03/28/2007 | EP1292298B1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 03/28/2007 | EP1254944B1 Dry compositions containing hydrophobic amino acid |
| 03/28/2007 | EP1233761B1 Osmotic dosage form comprising first and second coats |
| 03/28/2007 | EP1169349B1 Process for preparing gonadotropin compositions |
| 03/28/2007 | EP1019446B1 Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| 03/28/2007 | CN1938335A A simplified method to retrieve chitosan from acidic solutions thereof |
| 03/28/2007 | CN1938049A Polymer particles containing active agents |
| 03/28/2007 | CN1938048A 脂质体制剂 Liposomal formulations |
| 03/28/2007 | CN1938046A Monomethylvaline compounds capable of conjugation to ligands |
| 03/28/2007 | CN1938040A Oxytocin controlled release formulations and methods of using same |
| 03/28/2007 | CN1938034A ED-71 preparation |
| 03/28/2007 | CN1938033A Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle |
| 03/28/2007 | CN1938026A Controlled-release pharmaceutical composition and method for producing the same |
| 03/28/2007 | CN1938014A Solid preparation containing dibenz[b,e]oxepine derivative |
| 03/28/2007 | CN1938012A External preparation |
| 03/28/2007 | CN1938011A Pharmaceutical product containing tranilast |
| 03/28/2007 | CN1938008A Sustained-release preparations |
| 03/28/2007 | CN1938007A Controlled release formulation for oral administration of metformin |
| 03/28/2007 | CN1938003A Zinc preservative composition and method of use |
| 03/28/2007 | CN1935265A Grafted nano carbon anticancer prodrug, and its preparing method and use |
| 03/28/2007 | CN1935264A HPMC-polyhydric alcohol composite auxiliary material for slow-release tablet |
| 03/28/2007 | CN1935263A Nano carbon suspension injection |
| 03/28/2007 | CN1935259A Ultrasonic microvesicle as immuno adjuvant and vaccine carrier |
| 03/28/2007 | CN1935257A Therapeutic ultrasonic microvesicle for tumour ultrasonic therapy and its preparing method |
| 03/28/2007 | CN1935139A Substituted benzimidazole proton pump inhibitor composition, and its preparing method |
| 03/28/2007 | CN1935127A Method for preparing micro-spheres using modified ploylactic acid material as shell material |
| 03/28/2007 | CN1935126A Artemether self-emulified capsule and its preparing method |
| 03/28/2007 | CN1935121A Improved paclitaxel-based antitumor formulation |
| 03/28/2007 | CN1935120A Effervescent dry-mixed suspension agent |
| 03/28/2007 | CN1307253C Chitosan water-retaining gel adhesive substrate materials and method for preparing same |
| 03/28/2007 | CN1307200C Substantially homogeneous bio-affecting material having predetermined ratio of bio-affecting component to cell targeting component, method for making such material and use |
| 03/28/2007 | CN1306990C Multiple emulsions |
| 03/28/2007 | CN1306931C Capsule preparation |
| 03/28/2007 | CN1306929C Ultrapure oral fludara formulation with a fast releasing active substance |
| 03/28/2007 | CN1306919C Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| 03/28/2007 | CN1306916C Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use |
| 03/28/2007 | CN1306867C Ectoparasiticidal aqueous suspension formulations of Spinosyn |
| 03/27/2007 | US7196180 Amide derivatives; scaffold for tissue regeneration; drug delivery biodegradable; tissue adhesive |
| 03/27/2007 | US7196073 polysaccharide binding to surface receptor on antigen presenting cells |
| 03/27/2007 | US7196059 Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| 03/27/2007 | US7196056 A mixture comprising progenitor cells, are stimulated by exposure to a morphogen, tissue-specific cell differentiation and proliferation; tissue-targeted therapy, promoting liver tissue growth |
| 03/27/2007 | US7196054 Methods for treating wound tissue and forming a supplemented fibrin matrix |
| 03/27/2007 | US7195925 Polymer having an upper critical solution temperature |
| 03/27/2007 | US7195906 probiotics having immunomodulatory activity, used for prophylaxis gastrointestinal disorders such as inflammatory bowel disease or irritable bowel syndrome |
| 03/27/2007 | US7195780 Nanoparticle delivery system |
| 03/27/2007 | US7195779 Particularly levothyroxine sodium; unit dosage form containing an alditol, a saccharide, and optionally further excipients |
| 03/27/2007 | US7195778 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 03/27/2007 | US7195774 Surgically implantable and sealable drug delivery device that upon contact of its contents via an interface window or port with an organ or tissue exposes a therapeutic agent to organ or tissue surface, allowing a controlled, selective diffusion |
| 03/27/2007 | US7195769 Bioavailability |
| 03/27/2007 | US7195763 Treating or preventing infections; polyclonal and monoclonal antibodies |
| 03/27/2007 | US7195752 Surfactant compounds and uses thereof |
| 03/27/2007 | CA2431660C Stabilised radiopharmaceutical compositions |